Diabetes Core Update Podcasts

Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. Rosenstock et al. JAMA 2023;330(17):1631–1640. https://doi.org/10.1001/jama.2023.20294.

Impact of Guideline-Directed Statin Intervention for Primary Prevention in Patients With Diabetes. Muluk et al. Diabetes Care 2023;46(12):2273–2277. https://doi.org/10.2337/dc23-0816.

The Effectiveness of Shared Decision-making for Diabetes Prevention: 24- and 36-Month Results From the Prediabetes Informed Decision and Education (PRIDE) Trial. Duru et al. Diabetes Care 2023;46(12):2218–2222. https://doi.org/10.2337/dc23-0829.

Trends in Preventive Care Services Among U.S. Adults With Diagnosed Diabetes, 2008–2020 Wittman et al. Diabetes Care 2023;46(12):2285–2291. https://doi.org/10.2337/dc23-1119.

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Wadden et al. Nat Med 2023;29(11):2909–2918. https://doi.org/10.1038/s41591-023-02597-w.

Association Between Changes in Carbohydrate Intake and Long Term Weight Changes: Prospective Cohort Study. Wan et al. BMJ. 2023;382:e073939. https://doi.org/10.1136/bmj-2022-073939.

Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial. Bajaj et al. Ann Intern Med. 2023;Epub ahead of print. https://doi.org/10.7326/m23-1288.

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials. Rosenstock et al. Diabetes Care. 2023;46(11):1986–1992. https://doi.org/10.2337/dc23-0872.

Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU. Gunst et al. N Engl J Med 2023;389(13):1180–1190. https://doi.org/10.1056/nejmoa2304855.

Oral Semaglutide 50 mg Taken Once Per Day in Adults With Overweight or Obesity (OASIS 1): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Knop et al. Lancet 2023;402(10403):705–719. https://doi.org/10.1016/s0140-6736(23)01185-6.

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. Kosiborod et al. N Engl J Med. 2023;389(12):1069–1084. https://www.nejm.org/doi/10.1056/NEJMoa2306963.

Real-world Accuracy of CGM in Inpatient Critical and Noncritical Care Settings at a Safety-Net Hospital. Finn et al. Diabetes Care 2023;46(10):1825–1830. https://doi.org/10.2337/dc23-0089.

Leisure-Time Physical Activity and Risk of Microvascular Complications in Individuals With Type 2 Diabetes: A UK Biobank Study. Kristensen et al. Diabetes Care 2023;46(10):1816–1824. https://doi.org/10.2337/dc23-0937.

Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function. Herold et al. Diabetes Care 2023;46(10):1848–1856. https://doi.org/10.2337/dc23-0675.

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Wharton et al. N Engl J Med. 2023;389(10):877–888. https://www.nejm.org/doi/10.1056/NEJMoa2302392.

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Moura et al. Diabetes Care 2023;46(10):1807–1815. https://doi.org/10.2337/dc23-0492.

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Frias et al. Lancet 2023;402(10403):720-730. https://doi.org/10.1016/S0140-6736(23)01163-7.

Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade. Kalus et al. Diabetes Care 2023;46(9):1646–1651. https://doi.org/10.2337/dc23-0495.

A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA_1c ≥9–15%: DUAL HIGH Trial. Galindo et al. Diabetes Care 2023;46(9):1640–1645. https://doi.org/10.2337/dc22-2426.

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Rosenstock et al. Lancet 2023;402(10401):529-544. https://doi.org/10.1016/S0140-6736(23)01053-X.

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. Rosenstock et al. N Engl J Med 2023;Epub ahead of print. https://www.nejm.org/doi/10.1056/NEJMoa2303208.

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. Jastreboff et al. N Engl J Med 2023;Epub ahead of print. https://www.nejm.org/doi/10.1056/NEJMoa2301972.

Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis. Heerspink et al. Diabetes Care 2023;46(8):1501–1506. https://doi.org/10.2337/dc23-0261.

Relationship Among Diabetes, Obesity, and Cardiovascular Disease Phenotypes: A UK Biobank Cohort Study. Brown et al. Diabetes Care 2023;46(8):1531–1540. https://doi.org/10.2337/dc23-0294.

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Garvey et al. Lancet 2023;Epub ahead of print. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01200-X/fulltext.

Long-term effect of intensive lifestyle intervention on cardiometabolic risk factors and microvascular complications in patients with diabetes in real-world clinical practice: a 10-year longitudinal study. Tomah et al. BMJ Open Diabetes Res Care 2023;11(3):e003179. https://doi.org/10.1136/bmjdrc-2022-003179.

Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: systematic review and network meta-analysis. Karam et al. BMJ 2023; 380:e072003. https://doi.org/10.1136/bmj-2022-072003.

Beverage consumption and mortality among adults with type 2 diabetes: prospective cohort study. Ma et al. BMJ 2023;381:e073406. https://doi.org/10.1136/bmj-2022-073406.

Severe Mental Illness and Type 2 Diabetes Outcomes and Complications: A Nationwide Cohort Study. Fleetwood et al. Diabetes Care 2023;46(7):1363–1371. https://doi.org/10.2337/dc23-0177.

High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold. Castera et al. Diabetes Care 2023;46(7):1354–1362. https://doi.org/10.2337/dc22-2048.

Is COVID-19 to Blame? Trends of Incidence and Sex Ratio in Youth-Onset Type 2 Diabetes in Germany. Denzer et al. Diabetes Care 2023;46(7):1379–1387. https://doi.org/10.2337/dc22-2257.

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. Nissen et al. N Engl J Med 2023;388(15):1353-1364. https://www.nejm.org/doi/10.1056/NEJMoa2215024.

Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression. Rodriguez-Valadez et al. Diabetes Care 2023;46(6):1300–1310. https://doi.org/10.2337/dc22-0772.

A National Physician Survey of Deintensifying Diabetes Medications for Older Adults With Type 2 Diabetes. Pilla et al. Diabetes Care 2023;46(6):1164–1168. https://doi.org/10.2337/dc22-2146.

Higher Neighborhood Drivability Is Associated With a Higher Diabetes Risk in Younger Adults: A Population-Based Cohort Study in Toronto, Canada. den Braver et al. Diabetes Care 2023;46(6):1177–1184. https://doi.org/10.2337/dc22-1549.

Quantifying the Relationship Between Physical Activity Energy Expenditure and Incident Type 2 Diabetes: A Prospective Cohort Study of Device-Measured Activity in 90,096 Adults. Strain et al. Diabetes Care 2023;46(6):1145–1155. https://doi.org/10.2337/dc22-1467.

Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 Diabetes. Moran et al. JAMA Neurol Published online April 17, 2023. https://jamanetwork.com/journals/jamaneurology/article-abstract/2803244.

Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study. Wang et al. Diabetes Care 2023;46(5):967–977. https://doi.org/10.2337/dc22-1238.

Noninvasive Hypoglycemia Detection in People With Diabetes Using Smartwatch Data. Lehmann et al. Diabetes Care 2023;46(5):993–997. https://doi.org/10.2337/dc22-2290.

Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes. Wadwa et al. N Engl J Med. 2023;388(11):991–1001. https://www.nejm.org/doi/10.1056/NEJMoa2210834.

Safety and efficacy of an oral insulin (Capsulin) in patients with early-stage type 2 diabetes: A dose-ranging phase 2b study. New et al. Diabetes Obes Metab 2023;25(4):953–960. https://doi.org/10.1111/dom.14922.

Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial. Bue-Valleskey et al. Diabetes Care 2023;46(5):1060–1067. https://doi.org/10.2337/dc22-2396.

Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample. Tang et al. Ann Intern Med 2023;176(4):582-583. https://doi.org/10.7326/M22-3051.

Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration. Reaven et al. Diabetes Care 2023;46(4):854–863. https://doi.org/10.2337/dc22-2189.

Trends in the Prevalence of Lean Diabetes Among U.S. Adults, 2015–2020. Adesoba and Brown. Diabetes Care 2023;46(4):885–889. https://doi.org/10.2337/dc22-1847.

Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials. Pittas et al. Ann Intern Med 2023;176(3):355-363. https://doi.org/10.7326/M22-3018.

Low-Carbohydrate Diet Scores and Mortality Among Adults With Incident Type 2 Diabetes. Hu et al. Diabetes Care 2023;46(4):874–884. https://doi.org/10.2337/dc22-2310.

Trends in baseline HbA1c and body-mass index in randomised placebo-controlled trials of type 2 diabetes from 1987 to 2022: A systematic review and meta-analysis. Hu et al. EClinicalMedicine 2023;57:101868. https://doi.org/10.1016/j.eclinm.2023.101868.

How sweet is your love? Disentangling the role of marital status and quality on average glycemic levels among adults 50 years and older in the English Longitudinal Study of Ageing. Ford and Robitaille et al. BMJ Open Diabetes Res Care 2023. https://doi.org/10.1136/bmjdrc-2022-003080.

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study. Beernink et al. Diabetes Care 2023;46(3):602-607. https://doi.org/10.2337/dc22-1514.

An Examination of Whether Diabetes Control and Treatments Are Associated With Change in Frailty Index Across 8 Years: An Ancillary Exploratory Study From the Action for Health in Diabetes (Look AHEAD) Trial. Simpson et al. Diabetes Care 2023;46(3):519-525. https://doi.org/10.2337/dc22-1728.

Semaglutide Improves Cardiometabolic Risk Factors in Adults With Overweight or Obesity: STEP 1 and 4 Exploratory Analyses. Kosiborod et al. Diabetes Obes Metab 2023;25(2):468-478. https://doi.org/10.1111/dom.14890.

Glucagon Prescribing and Costs Among U.S. Adults With Diabetes, 2011–2021. Herges et al. Diabetes Care 2023;46(3):620-627. https://doi.org/10.2337/dc22-1564..

Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders. Rigby et al. Diabetes Care 2023;46(3):561–569. https://doi.org/10.2337/dc22-0908.

Youth-Onset Type 2 Diabetes: The Epidemiology of an Awakening Epidemic. Perng et al. Diabetes Care 2023;46(3):490-499. https://doi.org/10.2337/dci22-0046.

Dietary Factors and All-Cause Mortality in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Prospective Observational Studies. Barbaresko et al. Diabetes Care 2023;46(2):469-477. https://doi.org/10.2337/dc22-1018.

Prevalence and Predictors of Household Food Insecurity and Supplemental Nutrition Assistance Program Use in Youth and Young Adults With Diabetes: The SEARCH for Diabetes in Youth Study. Malik et al. Diabetes Care 2023;46(2):278-285. https://doi.org/10.2337/dc21-0790.

Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study. Wu et al. Diabetes Care 2023;46(2):297-304. https://doi.org/10.2337/dc22-1705.

Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study. Dimakos et al. Diabetes Care 2023;46(2):377-383. https://doi.org/10.2337/dc22-1584.

LY3437943, A Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist in People With Type 2 Diabetes: A Phase 1b, Multicentre, Double-Blind, Placebo-Controlled, Randomised, Multiple-Ascending Dose Trial. Urva et al. Lancet 2022;400(10366):1869-1881. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02033-5/fulltext.

Different Types of Industry-Produced and Ruminant Trans Fatty Acid Intake and Risk of Type 2 Diabetes: Findings From the NutriNet-Santé Prospective Cohort. Wendeu-Foyet et al. Diabetes Care 2023;46(2):321-330. https://doi.org/10.2337/dc22-0900.

Long-term Weight Training and Mortality in U.S. Male Health Professionals With and Without Type 2 Diabetes. Lee et al. Diabetes Care 2023;46(1):138–148. https://doi.org/10.2337/dc21-2420.

Trajectories of Cognition and Daily Functioning Before and After Incident Diabetes. Ji et al. Diabetes Care 2023;46(1):75–82. https://doi.org/10.2337/dc22-1190.

The Portfolio Diet and Incident Type 2 Diabetes: Findings From the Women's Health Initiative Prospective Cohort Study. Glenn et al. Diabetes Care 2023;46(1):28–37. https://doi.org/10.2337/dc22-1029.

Racial Disparities in Access and Use of Diabetes Technology Among Adult Patients With Type 1 Diabetes in a U.S. Academic Medical Center. Kanbour et al. Diabetes Care 2023;46(1):56–64. https://doi.org/10.2337/dc22-1055.

Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure. Cromer et al. Diabetes Care 2023;46(1):65–74. https://doi.org/10.2337/dc22-0383.

Sleep Duration and Risks of Incident Cardiovascular Disease and Mortality Among People With Type 2 Diabetes. Han et al. Diabetes Care 2023;46(1):101–110. https://doi.org/10.2337/dc22-1127.

Empagliflozin in Patients with Chronic Kidney Disease. The EMPA-KIDNEY Collaborative Group. N Engl J Med November 4, 2022. https://doi.org/10.1056/NEJMoa2204233.

Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease. Lamprea-Montealegre et al. Diabetes Care 2022;45(12):2900–2906. https://doi.org/10.2337/dc22-0614.

Relationship Between Carbohydrate Intake (Quantity, Quality, and Time Eaten) and Mortality (Total, Cardiovascular, and Diabetes): Assessment of 2003–2014 National Health and Nutrition Examination Survey Participants. Hou et al. Diabetes Care 2022;45(12):3024–3031. https://doi.org/10.2337/dc22-0462.

Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). de Boer et al. Diabetes Care 2022;45(12):3075–3090. https://doi.org/10.2337/dci22-0027.

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Rossing et al. Diabetes Care 2022;45(12):2991–2998. https://doi.org/10.2337/dc22-0294.

Effects of a Low-Carbohydrate Dietary Intervention on Hemoglobin A1c: A Randomized Clinical Trial. Dorans et al. JAMA Netw Open 2022;5(10):e2238645. https://doi.org/10.1001/jamanetworkopen.2022.38645.

Effects Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. Solomon et al. N Engl J Med 2022;387(12):1089-1098. https://doi.org/10.1056/NEJMoa2206286.

Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis. Poirrier et al. Diabetes Care 2022;45(11):2585–2593. https://doi.org/10.2337/dc21-2053.

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Heerspink et al. Lancet Diabetes Endocrinol 2022;10(11):774-785. https://doi.org/10.1016/S2213-8587(22)00243-1.

Productivity Loss and Medical Costs Associated With Type 2 Diabetes Among Employees Aged 18–64 Years With Large Employer-Sponsored Insurance. Park et al. Diabetes Care 2022;45(11):2553–2560. https://doi.org/10.2337/dc22-0445.

Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials. Yates et al. Diabetes Care 2022;45(11):2749–2752. https://doi.org/10.2337/dc22-0888.

Risk Factors for the Development of Retinopathy in Prediabetes and Type 2 Diabetes: The Diabetes Prevention Program Experience. White et al. Diabetes Care 2022;45(11):2653–2661. https://doi.org/10.2337/dc22-0860.

Effects of Patient-Driven Lifestyle Modification Using Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: Results From the Randomized Open-label PDF Study. Choe et al. Diabetes Care 2022;45(10):2224–2230. https://doi.org/10.2337/dc22-0764.

Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006–2020. Liaw et al. Diabetes Care 2022;45(10):2316–2325. https://doi.org/10.2337/dc22-0224.

Changes in Glucose Metabolism and Glycemic Status with Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants with Prediabetes in the STEP Program. Perreault et al. Diabetes Care 2022;45(10):2396–2405. https://doi.org/10.2337/dc21-1785.

Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. Korytkowski at al. The Journal of Clinical Endocrinology & Metabolism 2022;107(8):2101–2128. https://academic.oup.com/jcem/article/107/8/2101/6605637.

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Mosenzon et al. Diabetes Care 2022;45(10):2350–2359. https://doi.org/10.2337/dc22-0382.

Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA_1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Purola et al. Diabetes Care 2022;45(10):2445–2448. https://doi.org/10.2337/dc21-2298.

Optimal Number of Steps per Day to Prevent All-Cause Mortality in People With Prediabetes and Diabetes. Cruz et al. Diabetes Care 2022;45(9):2156–2158. https://doi.org/10.2337/dc22-0524.

Undiagnosed Diabetes in U.S. Adults: Prevalence and Trends. Fang et al. Diabetes Care 2022;45(9):1994–2002. https://doi.org/10.2337/dc22-0242.

Twenty-Year Temporal Trends in Risk of Ischemic Stroke in Incident Type 2 Diabetes: A Danish Population-Based Cohort Study. Gyldenkerne et al. Diabetes Care 2022;45(9):2144–2151. https://doi.org/10.2337/dc22-0440.

The Gut Microbiome Composition Is Altered in Long-standing Type 1 Diabetes and Associates With Glycemic Control and Disease-Related Complications. Van Heck at al. Diabetes Care 2022;45(9):2084–2094. https://doi.org/10.2337/dc21-2225.

Association of Metabolic Syndrome With Incident Dementia: Role of Number and Age at Measurement of Components in a 28-Year Follow-up of the Whitehall II Cohort Study. Machado-Fragua et al. Diabetes Care 2022;45(9):2127–2135. https://doi.org/10.2337/dc22-0206.

Changes in Visual Impairment due to Diabetic Retinopathy During 1980–2019 Based on Nationwide Register Data. Purola et al. Diabetes Care 2022;45(9):2020–2027. https://doi.org/10.2337/dc21-2369.

Management and Outcomes of Severe Hypoglycemia Treated by Emergency Medical Services in the U.S. Upper Midwest. Myers et al. Diabetes Care 2022;45(8):1788–1798. https://doi.org/10.2337/dc21-1811.

Diabetes Microvascular Disease Diagnosis and Treatment After High-Deductible Health Plan Enrollment. Wharam et al. Diabetes Care 2022;45(8):1754–1761. https://doi.org/10.2337/dc21-2563.

Model for Integration of Monogenic Diabetes Diagnosis Into Routine Care: The Personalized Diabetes Medicine Program. Zhang et al. Diabetes Care 2022;45(8):1799–1806. https://doi.org/10.2337/dc21-1975.

Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes Arslanian et al. NEJM June 4, 2022. DOI: 10.1056/NEJMoa2204601.

Dietary Protein Sources, Mediating Biomarkers, and Incidence of Type 2 Diabetes: Findings From the Women’s Health Initiative and the UK Biobank. Li et al. Diabetes Care 2022;45(8):1742–1753. https://doi.org/10.2337/dc22-0368.

Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Pop-Busui et al. Diabetes Care June 2022, Vol.45, 1670-1690. https://doi.org/10.2337/dci22-0014.

Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events in people with type 2 diabetes: A primary care cohort study. Whyte et al. Diabetes, Obesity and Metabolism, Volume 24, Issue 7, July 2022 https://doi.org/10.1111/dom.14705

Effect of Deintensifying Diabetes Medications on Negative Events in Older Veteran Nursing Home Residents Niznik et al. Diabetes Care May 2022, Vol.45, 1558-1567. https://doi.org/10.2337/dc21-2116.

Longitudinal Changes in Arterial Stiffness and Heart Rate Variability in Youth-Onset Type 1 Versus Type 2 Diabetes: The SEARCH for Diabetes in Youth Study. Shah et al. Diabetes Care June 2022, Vol.45, 1647-1656 https://doi.org/10.2337/dc21-2426.

Tirzepatide Once Weekly for the Treatment of Obesity Jastreboff et al. NEJM June 4, 2022. DOI: 10.1056/NEJMoa2206038.

Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). Kirwan et al. Diabetes Care March 2022, Vol.45, 1574-1583. https://doi.org/10.2337/dc21-2441.

Risks and burdens of incident diabetes in long COVID: a cohort study. Tie and Al-Aly. The Lancet VOLUME 10, ISSUE 5, P311-321, MAY 01, 2022. https://doi.org/10.1016/S2213-8587(22)00044-4.

Trends in Timing of and Glycemia at Initiation of Second-line Type 2 Diabetes Treatment in U.S. Adults. Raghavan et al. Diabetes Care 2022;45(6):1335–1345. https://doi.org/10.2337/dc21-2492

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials Tuttle et al. Diabetes Care 2022;45(6):1445–1452. https://doi.org/10.2337/dc21-2034.

Weight Change During the Postintervention Follow-up of Look AHEAD. Wing et al. Diabetes Care 2022;45(6):1306–1314. https://doi.org/10.2337/dc21-1990.

Progression to Diabetes Among Older Adults With Hemoglobin A1c–Defined Prediabetes in the US Koyama et al. JAMA Netw Open. 2022;5(4):e228158. 10.1001/jamanetworkopen.2022.8158.

Association Between Diabetes and Gray Matter Atrophy Patterns in a General Older Japanese Population: The Hisayama Study. Hirabayashi et al. Diabetes Care 2022;45(6):1364–1371. https://doi.org/10.2337/dc21-1911.

Changes in Physical Activity and the Risk of Dementia in Patients With New-Onset Type 2 Diabetes: A Nationwide Cohort Study. Yoo et al. Diabetes Care 2022;45(5):1091–1098. https://doi.org/10.2337/dc21-1597.

Trends in Prediabetes Among Youths in the US From 1999 Through 2018. Liu et al. AMA Pediatr. Published online March 28, 2022. doi:10.1001/jamapediatrics.2022.0077/

Adherence to the American Diabetes Association’s Glycemic Goals in the Treatment of Diabetes Among Older Americans, 2001–2018. Le et al. Diabetes Care 2022;45(5):1107–1115. https://doi.org/10.2337/dc21-1507.

Pregnancy Outcomes in Young Women With Youth-Onset Type 2 Diabetes Followed in the TODAY Study. TODAY Study Group. Diabetes Care 2022;45(5):1038–1045. https://doi.org/10.2337/dc21-1071.

Development and Progression of Diabetic Retinopathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study. TODAY Study Group. Diabetes Care 2022;45(5):1049–1055. https://doi.org/10.2337/dc21-1072.

Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults With Type 2 Diabetes and Overweight/Obesity: Results From the Look AHEAD Study. Look AHEAD Research Group. Diabetes Care 2022;45(5):1252–1259. https://doi.org/10.2337/dc21-1805.

The Incidence of Diabetes Among 2,777,768 Veterans With and Without Recent SARS-CoV-2 Infection. Wander et al. Diabetes Care 2022;45(4):782–788. https://doi.org/10.2337/dc21-1686.

Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Wright et al. Diabetes Care 2022;45(4):909–918. https://doi.org/10.2337/dc21-1113.

Persistence of Risk for Type 2 Diabetes After Gestational Diabetes Mellitus. Diaz-Santana et al. Diabetes Care 2022;45(4):864–870. https://doi.org/10.2337/dc21-1430.

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Rossing et al. Diabetes Care 2022;45(4):888–897. https://doi.org/10.2337/dc21-1944.

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Nelson et al. JAMA. 2022;327(2):138-150. doi:10.1001/jamanetworkopen.2021.48030.

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
The SURPASS-5 Randomized Clinical Trial. Dahl et al. JAMA. 2022;327(6):534-545. doi:10.1001/jama.2022.0078.

The carbohydrate-insulin model: a physiological perspective on the obesity pandemic. Ludwig et al. The American Journal of Clinical Nutrition, Volume 114, Issue 6, December 2021, Pages 1873–1885. https://doi.org/10.1093/ajcn/nqab270.

Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Champakanath et al. Diabetes Care 2022;45(3):750–753. https://doi.org/10.2337/dc21-2004.

Type 2 Diabetes, Glycemic Control, and Their Association With Dementia and Its Major Subtypes: Findings From the Swedish National Diabetes Register. Celis-Morales et al. Diabetes Care 2022;45(3):634–641. https://doi.org/10.2337/dc21-0601.

Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience. Palanca et al. Diabetes Care 2022;45(3):650–658. https://doi.org/10.2337/dc21-1584.

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial. Rubino et al. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619. doi:10.1001/jama.2021.23619.

Cost-Related Medication Nonadherence in Adults With Diabetes in the United States: The National Health Interview Survey 2013–2018. Taha et al. Diabetes Care 2022;45(3):594–603. https://doi.org/10.2337/dc21-1757.

Association of Bariatric Surgery With Cancer Incidence in Patients With Obesity and Diabetes: Long-term Results From the Swedish Obese Subjects Study. Sjöholm et al. Diabetes Care 2022;45(2):444–450. https://doi.org/10.2337/dc21-1335.

Universal Subsidized Continuous Glucose Monitoring Funding for Young People With Type 1 Diabetes: Uptake and Outcomes Over 2 Years, a Population-Based Study. Johnson et al. Diabetes Care 2022;45(2):391–397. https://doi.org/10.2337/dc21-1666.

Dietary Insulinemic Potential and Risk of Total and Cause-Specific Mortality in the Nurses’ Health Study and the Health Professionals Follow-up Study. Wan et al. Diabetes Care 2022;45(2):451–459. https://doi.org/10.2337/dc21-1530.

2022 National Standards for Diabetes Self-Management Education and Support. Davis et al. Diabetes Care 2022;45(2):484–494. https://doi.org/10.2337/dc21-2396.

Associations of Daily Steps and Step Intensity With Incident Diabetes in a Prospective Cohort Study of Older Women: The OPACH Study. Garduno et al. Diabetes Care 2022;45(2):339–347. https://doi.org/10.2337/dc21-1202.

Association of Statin Therapy Initiation With Diabetes Progression A Retrospective Matched-Cohort Study. Mansi et al. JAMA Intern Med. 2021;181(12):1562-1574. DOI: 10.1001/jamainternmed.2021.5714.

Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial. McInnes et al. Diabetes Care 2022;45(1):178–185. DOI: https://doi.org/10.2337/dc21-0278.

Gestational Diabetes Mellitus and the Risks of Overall and Type-Specific Cardiovascular Diseases: A Population- and Sibling-Matched Cohort Study. Yu et al. Diabetes Care 2022;45(1):151–159. https://doi.org/10.2337/dc21-1018.

Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. Agarwal et al. N Engl J Med 2021; 385:2507-2519. DOI: 10.1056/NEJMoa2110730.

Changes in the Prevalence of Symptoms of Depression, Loneliness, and Insomnia in U.S. Older Adults With Type 2 Diabetes During the COVID-19 Pandemic: The Look AHEAD Study. Chao et al. Diabetes Care 2022;45(1):74–82. https://doi.org/10.2337/dc21-1179.

Relationships of Changes in Physical Activity and Sedentary Behavior With Changes in Physical Fitness and Cardiometabolic Risk Profile in Individuals With Type 2 Diabetes: The Italian Diabetes and Exercise Study 2 (IDES_2). Pugliese et al. Diabetes Care 2022;45(1):213–221. https://doi.org/10.2337/dc21-1505.

Risk of Incident Dementia According to Glycemic Status and Comorbidities of Hyperglycemia: A Nationwide Population-Based Cohort Study. Lee et al. Diabetes Care 2022;45(1):134–141. https://doi.org/10.2337/dc21-0957.

The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Aleppo et al. Diabetes Care 2021 Dec; 44(12): 2729-2737. DOI: https://doi.org/10.2337/dc21-1304.

Long-term Occupational Consequences for Families of Children With Type 1 Diabetes: The Mothers Take the Burden. Dehn-Hindenberg et al. Diabetes Care 2021 Dec; 44 (12): 2656-2663. https://doi.org/10.2337/dc21-0740.

Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Lee et al. Diabetes Care 2021 Dec; 44 (12): 2775-2782. https://doi.org/10.2337/dc21-1046.

Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. Zhuo et al. JAMA Netw Open. 2021;4(10):e2130762. DOI:10.1001/jamanetworkopen.2021.30762.

Prediabetes Defined by First Measured HbA1c Predicts Higher Cardiovascular Risk Compared With HbA1c in the Diabetes Range: A Cohort Study of Nationwide Registries. Yahyavi et al. Diabetes Care 2021 Dec; 44 (12): 2767-2774. https://doi.org/10.2337/dc21-1062.

Trend of Diabetes-Related Hospital Admissions During the Transition Period From Adolescence to Adulthood in the State of California. Angel Siu Ying Nip and Maya Lodish. Diabetes Care 2021 Dec; 44 (12): 2723-2728. https://doi.org/10.2337/dc21-0555.

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. Pitt et al. N Engl J Med August 28, 2021. DOI: 10.1056/NEJMoa2110956.

Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database. Nagasu et al. Diabetes Care 2021 Nov; 44(11): 2542-2551. https://doi.org/10.2337/dc21-1081.

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Berg et al. Diabetes Care 2021 Nov; 44(11): 2573-2581. https://doi.org/10.2337/dc21-1170.

Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Anker et al. N Engl J Med 2021; 385:1451-1461. DOI: 10.1056/NEJMoa2107038.

Patient-Centered Goal-Setting in the National Diabetes Prevention Program: A Pilot Study. Ritchie et al. Diabetes Care 2021 Nov; 44(11): 2464-2469. https://doi.org/10.2337/dc21-0677.

Association of Type 2 Diabetes, According to the Number of Risk Factors Within Target Range, With Structural Brain Abnormalities, Cognitive Performance, and Risk of Dementia. van Gennip et al. Diabetes Care 2021 Nov; 44(11): 2493-2502. https://doi.org/10.2337/dc21-0149.

Replacement of Sedentary Behavior by Various Daily-Life Physical Activities and Structured Exercises: Genetic Risk and Incident Type 2 Diabetes. Li et al. Diabetes Care 2021 Oct; 44(10): 2403-2410. https://doi.org/10.2337/dc21-0455.

Glucose Regulation Beyond HbA1c in Type 2 Diabetes Treated With Insulin: Real-World Evidence From the DIALECT-2 Cohort. den Braber et al. Diabetes Care 2021 Oct; 44(10): 2238-2244. https://doi.org/10.2337/dc20-2241.

Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study. Harris et al. Diabetes Care 2021 Oct; 44(10): 2293-2301. https://doi.org/10.2337/dc21-0529.

Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Lind et al. Diabetes Care 2021 Oct; 44(10): 2231-2237. https://doi.org/10.2337/dc20-2439.

Nationwide Trends in Cardiac Risk and Mortality in Patients With Incident Type 2 Diabetes: A Danish Cohort Study. Gyldenkerne et al. Diabetes Care 2021 Oct; 44(10): 2353-2360. https://doi.org/10.2337/dc21-0383.

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Frías et al. N Engl J Med 2021; 385:503-515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519.

Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations. Stempniewicz et al. Diabetes Care 2021 Sep; 44(9): 2000-2009. https://doi.org/10.2337/dc20-2715.

Nutritional basis of type 2 diabetes remission. Taylor et al. BMJ 2021;374:n1449. https://doi.org/10.1136/bmj.n1449.

Chronic Kidney Disease Testing Among At-Risk Adults in the U.S. Remains Low: Real-World Evidence From a National Laboratory Database. Alfego et al. Diabetes Care 2021 Sep; 44(9): 2025-2032. https://doi.org/10.2337/dc21-0723.

Preparing for the NASH Epidemic: A Call to Action. Kanwal et al. Diabetes Care 2021 Sep; 44(9): 2162-2172. https://doi.org/10.2337/dci21-0020.

Diabetes and COVID-19: Population Impact 18 Months Into the Pandemic. Gregg et al. Diabetes Care 2021 Sep; 44(9): 1916-1923. https://doi.org/10.2337/dci21-0001.

High Out-of-pocket Health Care Cost Burden Among Medicare Beneficiaries With Diabetes, 1999–2017. Park et al. Diabetes Care 2021 Aug; 44(8): 1797-1804. https://doi.org/10.2337/dc20-2708.

Affect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. Martens T, Beck RW, Bailey R, et al. JAMA. 2021;325(22):2262–2272. doi:10.1001/jama.2021.7444.

Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes. Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R. JAMA. 2021;325(22):2273–2284. doi:10.1001/jama.2021.6530.

Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018. Fang et al. N Engl J Med 2021; 384:2219-2228. DOI: 10.1056/NEJMsa2032271.

Weight Loss by Low-Calorie Diet Versus Gastric Bypass Surgery in People With Diabetes Results in Divergent Brain Activation Patterns: A Functional MRI Study. Salem et al. Diabetes Care 2021 Aug; 44(8): 1842-1851. https://doi.org/10.2337/dc20-2641.

The Women’s Leadership Gap in Diabetes: A Call for Equity and Excellence. Dunne et al. Diabetes Care 2021 Aug; 44(8): 1734-1743. https://doi.org/10.2337/dci21-0015.

The Women’s Leadership Gap in Diabetes: A Call for Equity and Excellence. Dunne et al. Diabetes 2021 Aug; 70(8): 1623-1633. https://doi.org/10.2337/db21-0052.

High Burden of Subclinical and Cardiovascular Disease Risk in Adults with Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Commodore-Mensah et al. Diabetes Care 2021 Jul; 44 (7): 1657-1663. https://doi.org/10.2337/dc20-2227.

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. Lingvay et al. Diabetes Care 2021 Jul; 44(7): 1595-1603. https://doi.org/10.2337/dc20-2878.

Land Cover of Early-Life Environment Modulates the Risk of Type 1 Diabetes. Nurminen et al. Diabetes Care 2021 Jul; 44(7): 1506-1514. https://doi.org/10.2337/dc20-1719.

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. Bajaj et al. Diabetes Care 2021 Jul; 44(7): 1586-1594. https://doi.org/10.2337/dc20-2877.

Projecting the Incidence of Type 2 Diabetes–Related End-Stage Kidney Disease Until 2040: A Comparison Between the Effects of Diabetes Prevention and the Effects of Diabetes Treatment. Morton et al. Diabetes Care 2021 Jul; 44(7): 1515-1523. https://doi.org/10.2337/dc21-0220.

Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes. Walker et al. Diabetes Care 2021 Jul; 44(7): 1480-1490. https://doi.org/10.2337/dc20-2753.

Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care. Colling et al. Diabetes Care 2021 June; 44(6): 1443-1446. https://doi.org/10.2337/dc21-0013.

Important Drop Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. Roussel et al. Diabetes Care 2021 June; 44(6): 1368-1376. https://doi.org/10.2337/dc20-1690.

Frequency of Interruptions to Sitting Time: Benefits for Postprandial Metabolism in Type 2 Diabetes. Homer et al. Diabetes Care 2021 June; 44(6): 1254-1263. https://doi.org/10.2337/dc20-1410.

Renal Replacement Therapy in People With and Without Diabetes in Germany, 2010–2016: An Analysis of More Than 25 Million Inhabitants. Claessen et al. Diabetes Care 2021 June; 44(6): 1291-1299. https://doi.org/10.2337/dc20-2477.

Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial. Giugliano et al. Diabetes Care 2021 June; 44(6): 1353-1360. https://doi.org/10.2337/dc20-2623.

Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: A meta-analysis of randomized controlled trials. Silverii et al. Diabetes Obes Metab. 2021; 23: 1052– 1056. https://doi.org/10.1111/dom.14286.

Body Weight Changes During Pandemic-Related Shelter-in-Place in a Longitudinal Cohort Study. Lin et al. JAMA Netw Open. 2021;4(3):e212536. doi:10.1001/jamanetworkopen.2021.2536.

Risk of Progression to Diabetes Among Older Adults With Prediabetes. Rooney et al. JAMA. JAMA Intern Med. 2021;181(4):511-519. doi:10.1001/jamainternmed.2020.8774.

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Cahn et al. Diabetes Care 2021 May; 44(5): 1159-1167. https://doi.org/10.2337/dc20-2492.

Associations of Diet Quality and All-Cause Mortality Across Levels of Cardiometabolic Health and Disease: A 7.6-Year Prospective Analysis From the Dutch Lifelines Cohort. Vinke et al. Diabetes Care 2021 May; 44(5): 1228-1235. https://doi.org/10.2337/dc20-2709.

Associations Between Exposure to Gestational Diabetes Mellitus In Utero and Daily Energy Intake, Brain Responses to Food Cues, and Adiposity in Children. Luo et al. Diabetes Care 2021 May; 44(5): 1185-1193. https://doi.org/10.2337/dc20-3006.

Type 2 Diabetes Subgroups, Risk for Complications, and Differential Effects Due to an Intensive Lifestyle Intervention. Bancks et al. Diabetes Care 2021 May; 44(5): 1203-1210. https://doi.org/10.2337/dc20-2372.

Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding et al. N Engl J Med 2021; 384:989-1002. doi: 10.1056/NEJMoa2032183.

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial. Wadden TA, Bailey TS, Billings LK, et al. JAMA. Published online February 24, 2021. doi:10.1001/jama.2021.1831.

Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People With Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study. Ling et al. Diabetes Care 2021 Apr; 44(4): 915-924. https://doi.org/10.2337/dc20-0876.

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Persson et al. Diabetes Care 2021 Apr; 44(4): 1020-1026. https://doi.org/10.2337/dc20-1622.

Association of Metabolic Phenotypes With Coronary Artery Disease and Cardiovascular Events in Patients With Stable Chest Pain. Kammerlander et al. Diabetes Care 2021 Apr; 44(4): 1038-1045. https://doi.org/10.2337/dc20-1760.

Association of Objectively Measured Timing of Physical Activity Bouts With Cardiovascular Health in Type 2 Diabetes. Qian et al. Diabetes Care 2021 Apr; 44(4): 1046-1054. https://doi.org/10.2337/dc20-2178.

Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Dave et al. Circulation. 2021;143:770–779. https://doi.org/10.1161/CIRCULATIONAHA.120.047965.

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Frias et al. Diabetes Care 2021 Mar; 44(3): 765-773. https://doi.org/10.2337/dc20-1473

The SEE Study: Safety, Efficacy, and Equity of Implementing Autonomous Artificial Intelligence for Diagnosing Diabetic Retinopathy in Youth. Wolf et al. Diabetes Care 2021 Mar; 44(3): 781-787. https://doi.org/10.2337/dc20-1671

Prediabetes, Diabetes, and the Risk of All-Cause and Cause-Specific Mortality in a Japanese Working Population: Japan Epidemiology Collaboration on Occupational Health Study. Islam et al. Diabetes Care 2021 Mar; 44(3): 757-764. https://doi.org/10.2337/dc20-1213

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study Blonde et al. Diabetes Care 2021 Mar; 44(3): 774-780. https://doi.org/10.2337/dc20-2023

Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Patorno et al. Diabetes Care 2021 Mar; 44(3): 826-835. https://doi.org/10.2337/dc20-1464

Changes in Plant-Based Diet Indices and Subsequent Risk of Type 2 Diabetes in Women and Men: Three U.S. Prospective Cohorts. Chen et al. Diabetes Care 2021 Mar; 44(3): 663-671. https://doi.org/10.2337/dc20-1636

Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study. Lu et al. Diabetes Care 2021 Feb; 44(2): 549-555. https://doi.org/10.2337/dc20-1862

Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Lomonaco et al. Diabetes Care 2021 Feb; 44(2): 399-406. https://doi.org/10.2337/dc20-1997

Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. Abdul-Ghani et al. Diabetes Care 2021 Feb; 44(2): 433-439. https://doi.org/10.2337/dc20-0978

Glycemic Control and Risk of Cellulitis. Zacay et al. Diabetes Care 2021 Feb; 44(2): 367-372. https://doi.org/10.2337/dc19-1393

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Inzucchi et al. Diabetes Care 2021 Feb; 44(2): 586-594. https://doi.org/10.2337/dc20-1675

Association of Serum 25-Hydroxyvitamin D Concentrations With All-Cause and Cause-Specific Mortality Among Individuals With Diabetes. Wan et al. Diabetes Care 2021 Feb; 44(2): 350-357. https://doi.org/10.2337/dc20-1485

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. Rosenstock et al. N Engl J Med 2020; 383:2107-2116. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022474

The Impact of Bariatric Surgery on Incident Microvascular Complications in Patients With Type 2 Diabetes: A Matched Controlled Population-Based Retrospective Cohort Study. Singh et al. Diabetes Care 2021 Jan; 44(1): 116-124. https://doi.org/10.2337/dc20-0571

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. Bhatt et al. N Engl J Med November 16, 2020.DOI: 10.1056/NEJMoa2030186

Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000–2015. Cheng et al. Diabetes Care 2021 Jan; 44(1): 89-97. https://doi.org/10.2337/dc20-1913

Sedentary Time and Metabolic Risk in Extremely Active Older Adults. Madden et al. Diabetes Care 2021 Jan; 44(1): 194-200. https://doi.org/10.2337/dc20-0849

Severe Hypoglycemia, Cardiac Structure and Function, and Risk of Cardiovascular Events Among Older Adults With Diabetes. Echouffo-Tcheugui et al. Diabetes Care 2021 Jan; 44(1): 248-254. https://doi.org/10.2337/dc20-0552